摘要
目的观察曲美他嗪联合阿托伐他汀钙治疗不稳定型心绞痛的疗效及安全性。方法将100例不稳定型心绞痛患者随机分为治疗组和对照组,各50例。对照组常规给予硝酸酯类、钙离子拮抗剂、血管紧张素转换酶抑制剂、β受体阻滞剂、抗血小板药物等;治疗组在对照组常规治疗的基础上加用曲美他嗪和阿托伐他汀钙。两组均治疗8周。监测心电图及肌酸激酶、心绞痛控制情况及硝酸甘油消耗量;治疗前后检测总胆固醇、低密度脂蛋白胆固醇、C反应蛋白、白细胞计数及肝肾功能,并记录药物不良反应。结果治疗8周后,治疗组的总有效率显著高于对照组(P<0 01);治疗组总胆固醇、低密度脂蛋白胆固醇、C反应蛋白、白细胞计数均较治疗前显著下降(P<0.01);对照组治疗前后观察指标无显著差异(P>0.05);治疗组的心绞痛控制情况显著优于对照组(P<0.01);两组不良反应发生率无显著差异。结论曲美他嗪联合阿托伐他汀钙治疗不稳定型心绞痛安全有效。
Objective To investigate the efficacy and safety of Trimetazidine joint Atorvastatin calcium in the treatment of unstable angina pectoris （UAP）. Methods 100 cases of UAP were randomly divided into treatment group 50 cases and control group 50 cases. Conventional control group given nitrates, calcium antagonists, angiotensin -converting enzyme inhibitor, β - blockers, anti - platelet drug, etc. ; the treatment group in the control group based on conventional therapy plus Trimetazidine and Atorvastatin calcium. Both groups were treated for 8 weeks. Monitoring of ECG and creatine kinase, control angina and nitroglycerin consumption; treatment before and after the detection of TC, LDL - C, CRP, WBC, and liver and kidney function, and recording adverse drug reactions. Results The results after 8 weeks treatment, the treatment group the total effective rate was siguificantly higher （P 〈 0. 01 ） ; treatment group TC, LDL - C, CRP, WBC were significantly decreased before treatment （P 〈 0. 01 ） ; the control group indicators before and after the observation of no significant difference （P 〉 0. 05 ） ; The treatment of angina control group was significantly better than the control group （P 〈 0. 01 ） ; 2 group the incidence of adverse reactions was no significant difference. Conclusion Trimetazidine joint Atorvastatin calcium in the treatment of unstable angina is salty and effective.
出处
《中国医学创新》
CAS
2010年第2期32-34,共3页
Medical Innovation of China
